Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review".

Goncalves J, Caliceti P

Open source

DOI
10.1007/s40259-025-00724-2
Published
2025 Jul
Container
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40259-025-00724-2,
  title = {Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review".},
  author = {Goncalves J and Caliceti P},
  year = {2025},
  journal = {BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy},
  doi = {10.1007/s40259-025-00724-2},
  url = {https://doi.org/10.1007/s40259-025-00724-2}
}

RIS

TY  - JOUR
TI  - Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review".
AU  - Goncalves J
AU  - Caliceti P
PY  - 2025
JO  - BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
DO  - 10.1007/s40259-025-00724-2
UR  - https://doi.org/10.1007/s40259-025-00724-2
ER  - 

APA

J, G., & P, C. (2025). Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review".. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. https://doi.org/10.1007/s40259-025-00724-2

Source records